Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads by Date Must reads for theWeek ending May 10, 2020 Novel inflammatory syndrome in children possibly linked to COVID-19, Transplant beats bortezomib-based therapy for MM, but questions remain, Vaccine maintenance improves relapse-free survival in BRCA wild-type ovarian cancer, COVID-19 pulmonary severity ascribed to coagulation differences, Interleukin-27 increased cytotoxic effects of bone marrow NK cells in CLL, More must reads Must reads for theWeek ending May 3, 2020 Adding a blood test to standard screening may improve early cancer detection, Case series suggests biologics, JAK inhibitors safe during pandemic, Antitumor treatment may increase risk of severe events in COVID-19 patients, Circulating biomarker, genetic data improve pancreatic cancer risk modeling in general population, IDSA guidelines cover N95 use and reuse, More must readsMust reads for theWeek ending April 26, 2020 EBV, HIV infection not associated with DLBCL subtypes, High TCL1 expression associated with poor prognosis in patients with DLBCL, Academic centers had significantly improved DLBCL survival over nonacademic centers, Developing a taxonomy of DLBCL and its subtypes with relevance to outcomes, Using informatics to identify DLCBL subgroups, drug-gene interactions, More must readsMust reads for theWeek ending April 19, 2020 N.Y. universal testing: Many COVID-19+ pregnant women are asymptomatic, CLAM trial regimen shown safe, effective for r/r AML, Update confirms survival benefit with trastuzumab in uterine serous carcinoma, Severe COVID-19 may lower hemoglobin levels, Survey reveals gender pay discrepancies among gyn-oncs, More must readsMust reads for theWeek ending April 12, 2020 Cardiovascular problems already apparent in children with hemophilia A, Breastfeeding reduces invasive ovarian cancer risk, Monocytic AML subclones can cause resistance to venetoclax, Monensin shows promise as a molecular scaffold for inhibiting AML, TRIM31 promotes AML progression, resistance to daunorubicin, More must readsPages« first 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 last »
